aTyr Pharma reported $10.01M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Ardelyx USD 31.21M 36.79M Mar/2026
aTyr Pharma USD 10.01M 735K Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 90.6M 83.14M Dec/2025
CSL USD 2.16B 633M Jun/2025
Curis USD 10.14M 10.14M Jun/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
United Therapeutics USD 1.28B 277.4M Mar/2026
Xoma USD 143.9M 7.68M Jun/2024